Outcomes and Safety of Metabolic and Bariatric Surgery for Mild Obesity
Overview
This study evaluates the mid-term outcomes of metabolic and bariatric surgery (MBS) in Asian patients with mild obesity compared to those with higher BMI. Results indicate that while patients with mild obesity experienced lower total weight loss, they achieved similar metabolic improvements and a higher rate of normalization of body weight.
Background
The rising prevalence of obesity, particularly in Asia, poses significant public health challenges, with mild obesity being a rapidly growing subgroup. Traditional management strategies often yield modest results, highlighting the need for effective interventions. MBS has shown promise in providing durable metabolic benefits, yet its role in patients with mild obesity remains underexplored.
Data Highlights
Group
% Total Weight Loss (%TWL)
Composite Metabolic Endpoint Achieved (%)
Mild Obesity (BMI 27.5-32.5 kg/m²)
~20%
30.7%
Higher BMI (BMI ≥32.5 kg/m²)
~26%
27.6%
Key Findings
Mild obesity patients achieved approximately 20% total weight loss compared to 26% in higher BMI patients (P < 0.05).
Both groups had comparable rates of achieving the composite metabolic endpoint (30.7% vs 27.6%, P = 0.76).
Significant improvements in glycemic control, lipid profile, blood pressure, and insulin resistance were observed in both groups.
Remission of type 2 diabetes, hypertension, hyperuricemia, and metabolic-associated fatty liver disease increased significantly (all P < 0.05).
A greater proportion of mild obesity patients achieved normalization of body weight (BMI <24 kg/m²).
Complication rates were low and comparable between both groups.
Clinical Implications
MBS can be considered a safe and effective intervention for Asian patients with mild obesity, offering similar metabolic benefits as seen in higher BMI cohorts. Clinicians should weigh the potential for significant metabolic improvements against the lower total weight loss when discussing surgical options with patients.
Conclusion
MBS provides durable metabolic benefits for Asian patients across BMI categories, suggesting its potential role in managing mild obesity. Further research is warranted to confirm these findings and explore long-term outcomes.
A four-factor staging system stratified response rates from 90.9% to 37.5% in a retrospective cohort study, although the model showed only moderate discrimination (C statistic, 0.68) and requires external validation
